Oncology · Colorectal CancerTrial Updateclinicalmid-term

Study on mFOLFOX6+Bevacizumab+PD-1 in Local Advanced MSS CRC Initiated

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/2/2026, 6:31:13 AM

Assessment confidence: 73% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of this clinical trial represents a significant opportunity for advancing treatment options in the colorectal cancer space, particularly for the majority of patients with pMMR/MSS CRC. Positive outcomes could reshape treatment protocols and enhance the competitive positioning of involved therapies. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 7 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should monitor this trial closely as positive results could lead to new indications for existing therapies and impact market dynamics in CRC treatment. The strongest clinical anchor is mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC (ClinicalTrials.gov), sub-indication match (colorectal cancer); mechanism alignment (pd-1). Successful trial results may lead to new indications for existing therapies, potentially increasing market share and revenue in the colorectal cancer treatment segment.

Competitive Pressure

The most relevant competitive pressure comes from If successful, this combination could provide a new treatment option for the majority of CRC patients who are pMMR/MSS, potentially altering the treatment landscape..

Regulatory Outlook

Regulatory risk is concentrated around If the trial demonstrates efficacy, it could prompt changes in treatment guidelines and regulatory approvals for the combination therapy, impacting compliance and market access..

Key Risks

Elevated medium regulatory exposure for Bevacizumab could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

Successful trial results may lead to new indications for existing therapies, potentially increasing market share and revenue in the colorectal cancer treatment segment.
Portfolio teams should monitor this trial closely as positive results could lead to new indications for existing therapies and impact market dynamics in CRC treatment.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results and overall survival data from the trial, as well as any changes in treatment guidelines for MSS CRC.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (indication); Broad oncology match without sub-indication specificity
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (indication); Broad oncology match without sub-indication specificity
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer); Mechanism alignment (PD-1)
FDA document
View source
Study of Voicing My CHOiCES as Tool for Advanced Care Planning in Young Adults With Cancer
ClinicalTrials.govlow relevance
Patient population match (advanced)
FDA document
View source
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
ClinicalTrials.govlow relevance
Patient population match (advanced)
FDA document
View source
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
ClinicalTrials.govlow relevance
Patient population match (advanced)
FDA document
View source
ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
ClinicalTrials.govlow relevance
Patient population match (advanced)
FDA document
View source

Cabozantinib plus Nivolumab Shows Promise in Advanced Non-Clear Cell RCC
Humanexa Signalslow relevance
Patient population match (advanced); Broad oncology match without sub-indication specificity

Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Mechanism alignment (PD-1)
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Cost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling study.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Altered crosstalk of bacterial lipopolysaccharide with immune cells in colorectal cancer compared to paired adjacent intestinal tissue.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
ADAR1-circRAB5A-BIP axis governs radiotherapy resistance in colorectal cancer through coordinating protective autophagy and apoptosis.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedlow relevance
Patient population match (advanced)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Bevacizumab
PD-1 monoclonal antibody

Commercial impact

high

Successful trial results may lead to new indications for existing therapies, potentially increasing market share and revenue in the colorectal cancer treatment segment.

Regulatory impact

medium

If the trial demonstrates efficacy, it could prompt changes in treatment guidelines and regulatory approvals for the combination therapy, impacting compliance and market access.

What to watch

Key milestones include interim results and overall survival data from the trial, as well as any changes in treatment guidelines for MSS CRC.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.